Key result
This editorial discusses the ACUITY trial, which evaluated the thrombin-specific anticoagulant bivalirudin as part of a blended medical and invasive strategy for acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
An editorial discussing the ACUITY trial, which evaluated bivalirudin in patients with acute coronary syndromes undergoing invasive procedures.
The treatment of patients with acute coronary syndromes is straightforward in principle but complex in practice. With the increase in referrals of moderate- or high-risk patients for invasive cardiac procedures to improve clinical outcomes,1 there is a need to define the antithrombotic regimen that is optimal for both stabilizing the underlying active atherosclerotic plaque and minimizing the risk of bleeding.The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, reported in this issue of the Journal, 2 evaluated the role of a thrombin-specific anticoagulant — bivalirudin — as part of a blended medical and invasive strategy for patients with acute . . .
No takes yet. Share an insight, caveat, or question.
John A. Bittl (2006) conducted an editorial in acute coronary syndromes. bivalirudin was evaluated. This editorial discusses the ACUITY trial, which evaluated the thrombin-specific anticoagulant bivalirudin as part of a blended medical and invasive strategy for acute coronary syndromes.
Synapse has enriched 10 related papers. Consider them for comparative context: